INTRODUCTION
Although multiple oncogenes that activate signaling pathways directly involved in cell survival or proliferation have been discovered in the last decades, many other genes that provide an advantage to the tumoral cells making them insensitive to physiological signals or altering their normal physiology are still to be found. Functional genetic screens using retroviral delivery of high complexity cDNA libraries constitute a valuable tool to discover new genes involved in the appropriate phenotypic characteristic of the tumorigenic process [1] [2] [3] . A genome-wide retroviral cDNA screen to search for genes that confer cancer cells selective advantage during tumorigenesis allowed us to identify MAP17 [4] , a small non-glycosylated membrane-associated protein of 17 kDa that locates to the plasma membrane and the Golgi apparatus [5, 6] . The protein sequence showed a hydrophobic amino-terminus of 13 aminoacids encoding a PDZ binding domain and two transmembrane regions [7, 8] . MAP17 was first described by differentital display overexpressed in carcinomas [5] . Transfection of full length wild type MAP17 into HT29 colon carcinoma cells decreased cell proliferation in vitro and tumor growth in vivo [6] . MAP17 binds several PDZ domain-containing proteins, including PDZK1, NHERF proteins, NaPiIIa and NHe3. Overexpression of MAP17 into opossum kidney cells participates, together with NHRF3 and NHRF4 in NaPiIIa internalization to the transgolgi network [8] . In a transgenic mouse model, MAP17 hepatic overexpression resulted in PDZK1 liver deficiency, suggesting that MAP17 is an endogenous regulator of PDZK1 turnover [9] . MAP17 acts as an atypical anchoring site for PDZK1 and interacts with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells [10] . The physiological role of MAP17 in proximal tubules is not known but it stimulates specific Na-dependent transport of mannose and glucose in Xenopus oocytes [11] . MAP17 share regulatory elements with the stem cell leukemic gene (SCL, TAL-1) a basic HLH protein essential in the formation of the hematopoietic lineages [12, 13] , although, major expression of MAP17 has been found only in kidney among normal tissues.
MAP17 is overexpressed, mostly through mRNA amplification, in a great variety of human carcinomas [5, 14] . Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostatic and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression. Many tumor cells also express MAP17 and its expression does not correlate with expression of SCL a neighbor gene reported to be coexpressed in some hematopoietic cell lines. SCL neither is expressed in most MAP17 positive tumors, indicating the independent transcription of MAP17, al le ast in carcinomas [14] . Moreover we have found that MAP17 promoter is activated by oncogenes [14] .
However, the known facts data do not provide an explanation why MAP17 could be overexpressed in some carcinoma tumors nor the reason to be selected in a phenotypic screen providing selective advantage during tumorigenesis. In the present work we describe how MAP17 enhances the tumorigenic properties of tumoral cells, providing them a selective advantage during cancer progression. Moreover, 
EXPERIMENTAL PROCEDURES
Cell culture. A375 malignant melanoma cells from ATCC were maintained in Dulbecco´s modified Eagle´s medium with glutamax (Gibco) containing 10% fetal bovine serum (Sigma), penicillin, streptomycin and fungizone. Cultures were selected w hen indicated with 75 µg/ml hygromycin (Calbiochem), 400 µg/ml G418 (Sigma) or 2 µg/ml Puromycin (Fluka). To perform the gene transfer using ecotropic competent retroviruses, cells were transfected with the murine receptor and a mass culture expressing the receptor used for the following experiments. Human MAP17 full cDNA and mutant were cloned in pBabepuro and clones generated by gene transfer. Numerous clones were selected and tested. All behave similarly. For this work 4 representative clones were used.
Retroviral-Mediated Gene Transfer.
Packaging LinXE cells were plated in a 10 cm dish, incubated for 24 h and then transfected by calcium phosphate precipitation with 20 µg of the retroviral plasmid (16 h at 37°C). After 48 h, the virus-containing medium was filtered (0.45 µm filter, Millipore) and supplemented with 8 µg/ml polybrene (Sigma) and an equal volume of fresh medium. Target cells were seeded at 10 6 cells/10 cm dish and incubated overnight. For infections, the culture medium was replaced by the appropriate viral supernatant; the culture plates were centrifuged (1 h, 1500 rpm) and incubated at 37°C for 16 h. The infected cell population was purified using the appropriate selection.
RT-PCR.
Total RNA was purified using the TRI-REAGENT (Molecular Research Center, Cincinnati Ohio). Reverse transcription was performed with 5 µg of mRNA using MMLV reverse transcriptase (Promega) and oligodT primer according to the manufacturer's recommendations. The following primers were used to amplify specific cDNA regions: MAP17 forward 5´-CAGCCATGTCGGCCCTCA-3´ and reverse 5´-TTATTTCACAGAAATTAGGGCC-3´; ?-actin:
forward 5´-AGGCCAACCGCGAGAAGATGAC-3´ and reverse 5´-GAAGTCCAGGGCGACGTAGCA-3´. cDNA was subjected to PCR under standard conditions (95ºC 30'', 65ºC 45'', 72ºC 45''; 30 cycles) and products were analyzed by 1% agarose gel electrophoresis. Wound-healing assays. An artificial "wound" was created using a 10 µl pipette tip on confluent cell monolayer in 4-chambers plates (Lab-Tek II chambered 1.5 coverglass system 155382 Nalge Nunc International) in complete medium. Photographs were taken every 10 minutes during 12 hours using a Confocal Ultra-Spectral microscope Leica TCS-SP2-AOBS-UV.
Surrogated assays

MAP17
Protein determination. 10 6 cells were resuspended in 100 µl of phosphate-buffered saline. Monoclonal MAP17 antibody was generated from bacterial purified GST-MAP17 protein ( [14] 
RESULTS
MAP17 confers proliferative advantage in full serum conditions to human melanoma cells
To study the biological effect of MAP17 we selected human tumor cells that do not express MAP17 mRNA, expressed the wild type human MAP17 cDNA and studied the alteration of the biological properties of these cells. To that end, we selected A375 from human melanoma cells. First, we generated To determine their ability to overcome apoptosis in the absence of cell contact, we measured the capability to form colonies when cells were seeded at very low density. We plated 10 3 cells per 10 cm dish and cultured them during one week in complete medium. MAP17 expressing cells formed 2 to 4 fold more colonies in these conditions than parental A375 cells expressing only the vector ( Figure 2C ), indicating that MAP17 enhanced the survival of these cells in the absence of cell contact.
We also determined the ability of the clones to grow in anchorage independent conditions. We seeded 10 4 cells from parental or MAP17 expressing clones in soft agar and cultured them for 3 weeks.
While parental A375 cells produced only few small colonies, MAP17 expressing clones produced a high number of larger colonies (Figures 2 D and E).
To check whether MAP17 modifies the migration capability of the cells, we performed an in vitro wound-filling assay. Cells were seeded in 4-chamber slides and once they reached confluence we generated a wound in the cell monolayer and measured their ability to close the wound. MAP17
expressing clones showed a greatly increased ability to migrate and to close the wound (Figures 2F and G).
To confirm these properties in a more physiological setting we injected parental A375 cells or MAP17 expressing clones into nude mice and followed the growth of the xenografts. Thus, the ectopic expression of MAP17 in melanoma cells is associated with the enhancement of malignant cell behavior, indicating that MAP17 is implicated in growth rate, survival in the absence of cell contact, anchorage-independent growth, motility and tumorigenicity in nude mice.
The enhanced oncogenic capabilities induced by MAP17 in tumoral cells are due to an increase of intracellular ROS.
Growing evidence suggests that reactive oxygen species (ROS) act as second messengers in intracellular signaling cascades that induce and maintain the oncogenic phenotype of tumoral cells. ROS have been described to induce proliferation, survival and cellular migration [15] [16] [17] . We have observed that MAP17 is able to induce similar properties in tumor cells; therefore we investigated whether have, in average, 30% more intracellula r ROS than parental cells. This increase in ROS levels was inhibited by glutathione (GSH) (Figure 4B ), the most important low molecular size thiol involved in cellular detoxification, redox balance and stress response, and by and N-acetyl-cysteine (NAC), another important ROS scavenger (Fig 4B) .
In transformed fibroblasts, Ras and Rac appear to be directly linked to the production of superoxide anions and in turn, transformation of these cells depends on ROS formation since it can be suppressed by treatment with antioxidants [18] . We checked whether some of the transforming properties of MAP17 were linked to the detected intracellular ROS increase. To that end we examined clonability, growth in soft agar and in vitro wound filling in the presence of antioxidants. We found that the presence of antioxidants reduced the oncogenic propertie s of the MAP17 expressing cells: they have reduced colony formation efficiency in the presence of antioxidants (Fig 4C) and the average colony size is dramatically reduced as an indication of reduced growth rate ( Figure 4D ). Interestingly, the colony formation efficiency and colony size are similar to parental cells in the absence of antioxidants.
The same effect was found in the soft agar growth assay: antioxidants reduced the number and size of colonies of MAP17-expressing cells (Fig 4E and F) . Finally, the presence of antioxidants inhibits the ability to migrate and fill the wound in MAP17-expressing cells ( Figure 4G ).
Our data indicate that the expression of MAP17 in human melanoma cells induces an increase of intracellular ROS that plays an important role in the enhancement of the malignant cell behavior.
MAP17-dependent ROS increase and tumorigenesis are dependent on its PDZ-binding domain.
MAP17 structure is reduced to two transmembrane regions and one PDZ-binding domain. MAP17
binds several PDZ domain-containing proteins, including PDZK1, NHERF proteins, NaPiIIa and NHe3.
To study whether the effect of MAP17 overexpression was related to its ability to bind PDZ domain containing proteins, we generated a mutant MAP17 protein in which 2 amino acids out the 4 comprising the PDZ-binding domain were mutated disrupting the structure (Fig 5A) . We generated individual clones carrying mutant MAP17 ( Figure 5B and C) and measured its ability to enhance the tumorigenic propertines of A375 cells. MAP17 defective in its PDZ-binding domain was unable to increase growth rate, clonability or growth in soft agar ( Figure 5 D-G) . These results confirm that the biological effect produced by MAP17 was dependent on its PDZ-binding domain.
We have also shown that this effect it is also dependent on ROS increase. Therefore, we measured whether both effects were linked. We measured ROS levels in A375 expressing mutated MAP17.
MAP17 defective in its PDZ-binding domain was unable to increase intracellular ROS ( Figure 5 H) .
Inhibition of Na + -coupled co-transporters inhibits MAP17-dependent ROS increase and tumorigenesis.
MAP17 stimulates specific Na + -dependent transport of mannose and glucose in Xenopus oocytes [11] and this activity is sensitive to known inhibitors of Na + -coupled co-transporters [19] . Furosemide acts by inhibiting the Na-K-2Cl symporter while Phloridzin inhibits the Na + -coupled glucose
transporters. Therefore, we tested whether MAP17-dependent ROS increase was dependent on Na To that end, we tested proliferation, clonability, growth in soft agar in the presence of both drugs. We found that the treatment with phloridzin and furosemide reduced the oncogenic properties of the MAP17 expressing cells: they have reduced growth rate at least during the first 4 dais in culture. Later they seems to adapt and recover full growing capabilities ( Figure 6B ). Colony formation efficiency in the presence of inhibitors also was reduced (Fig 6C) . The same effect was found in the soft agar growth assay: phloridzin reduced the number and size of colonies of MAP17-expressing cells (Fig 6D and E) .
Therefore, inhibition of Na + -coupled co-transporters inhibits MAP17-dependent ROS increase and tumorigenesis.
DISCUSSION
Melanoma cells that stably express MAP17 show an increased tumoral phenotype, with enhanced proliferative capabilities both in presence or absence of cell contact, decreased apoptotic sensitivity and increased migration. Moreover, we found that MAP17 is overexpressed, mostly through mRNA amplification, in a great variety of human carcinomas [14] . The increased tumorigenic potential observed with the expression of MAP17 cDNA is in accordance with the i ncreased expression of MAP17 observed in tumors, specially in ovarian and prostate tumors, where MAP17 levels are associated with malignant stages [14] .
An initial report (6) described that overexpression in human carcinoma cells HT29 lead to a decrease in growth. We do not know the discrepancy between our data and those from Kocher and cols. [38] . Whatever the proximal target(s), ROS reprogram the expression of enzymes and other proteins in the cell [39, 40] . DNA microarray experiments [26] indicate that up to 2% of the 6,500 genes queried are regulated by ROS. Furthermore, we have found that ROS increase activates PI3K pathway, probably by direct oxidation and inactivation of PTEN and other AKT phosphatases, maintaining AKT activated even in the absence of PI3K signal (Guijarro et al, submitted). AKT pathway activation induced by MAP17 expression might explain some of the properties described here. However, we think that other pathways must coexist induced by MAP17 at transcriptional level, as described in other systems [39, 40] .
But, how are ROS increased by MAP17? One possibility is that MAP17 can increase glucose and mannose uptake, inducing an increase in metabolism and ROS as side product. However, the enforced increase of the intracellular mannose or glucose level without MAP17 overexpression does not alter the tumorigenic properties of the cells (Data not shown). We therefore favor a hypothesis in which ROS are generated with the direct participation of MAP17.
It has been proposed that the effect of MAP17 most likely consists in an enhancement of the endogenous uphill transport system [11] . MAP17 also presents a weak similarity with ATP synthases, Na-solute transporters and transferases. However, both the structural simplicity of MAP17 and the kinetic analysis of the induced transport [11] suggest that MAP17 is an activator of the capacity of an endogenous transporter. We suggest that MAP17 enhances the activity of membrane transporters, thus inducing an increase in intracellular ROS. Subsequently, this increase in ROS causes the increase in the malignant behavior of tumoral cells. We have tested this hypothesis using Na+-coupled transporters inhibitors. These inhibitors block MAP17-dependent ROS increase in A375 cells and subsequent encancement of malignant behavior, confirming the role of membrane transporters in MAP17 effect.
MAP17 could modulate the activity or the organization of membrane transport through direct interaction as the RS1 modifier does [41] , or through competition for PDZ binding places to alter the stoichiometry of the transporter-PDZ proteins [11] . The structural simplicity of MAP17 supports this regulatory role. Furthermore, we suggest that MAP17 increased tumorigenesis is dependent upon Na+-coupled transport dependent ROS increase.
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